Benefit of transplantation after Complete Response In Patients with T-cell lymphoma

Phase 1

Recruiting

• Conditions: Peripheral T-cell lymphoma (PTCL); MedDRA version: 21.1Level: PTClassification code: 10034623Term: Peripheral T-cell lymphoma unspecified Class: 100000004864; Therapeutic area: Diseases [C] - Neoplasms [C04]

• Registration Number: CTIS2022-501710-62-02
• Lead Sponsor: ysarc

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-01-10
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 204

Inclusion Criteria

Patient = 18 years and < 70 years of age at the time of signing the informed consent form (ICF), Patient who understood and voluntarily signed and dated an informed consent prior to any study-specific assessments/procedures being conducted, Able to adhere to the study visit schedule and other protocol requirements, Patient covered by any social security system, Patient who understands and speaks one of the country official languages, Males with partners of childbearing potential must agree to use effective birth control methods during the study as informed by the investigator in accordance with SmPC of each drugs administrated, Females of childbearing potential must agree to use effective birth control methods for at least 28 days before starting treatment; while participating in the study; during treatment interruptions and necessary period after the study as informed by the investigator in accordance with SmPC of each drugs administrated, Patient fit enough to receive autologous stem cell transplant as a consolidation strategy as assessed by the local investigator, Hemoglobin level > 8g/dL (transfusion allowed); Neutrophil count >0.5 G/L; Platelets count > 50 G/L (transfusion allowed), Patient with histologically proven nodal-type peripheral T-cell lymphoma (PTCL)” (latest WHO classification), not previously treated; as defined by the WHO classification, the following subtypes may be included, oPTCL, not otherwise specified oFollicular helper T-cell lymphomas: Angioimmunoblastic T-cell lymphoma and nodal PTCL with TFH phenotype and follicular T-cell lymphoma oAnaplastic large cell lymphoma, ALK-negative, Ann Arbor staging (I-IV) except stage I with normal LDH and PS<2 (i.e. stage I aaIPI 0), Participant with a measurable disease by the Lugano criteria (i.e., longest diameter of a nodal site > 1.5 cm and/or longest diameter of an extranodal site > 1.0 cm and/or a hypermetabolic lesion), FFPE Diagnostic tissue block should be available for central pathology review and ancillary molecular analyses, Participant with Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2, Estimated minimum life expectancy of 3 months

Exclusion Criteria

Known central nervous system or meningeal involvement by lymphoma, Pregnant, planning to become pregnant or lactating WOCBP, Any significant medical conditions, laboratory abnormality or psychiatric illness likely to interfere with the participation in this clinical study (according to the investigator’s decision), Person deprived of his/her liberty by a judicial or administrative decision, Person hospitalized without consent, Adult person under legal protection, Impaired renal function (calculated MDRD or Cockcroft-Gault Creatinine Clearance < 30 ml/min) or impaired liver function tests (serum total bilirubin level > 2.0 mg/dl [34 µmol/L] (except in case of Gilbert’s Syndrome, or documented liver or pancreatic involvement by lymphoma), serum transaminases (AST or ALT) > 3 upper normal limit unless they are related to the lymphoma., The following types of T-cell lymphomas: oAdult T-cell lymphoma/leukemia (HTLV-1 related T-cell lymphoma) oExtranodal T-cell/NK-cell lymphoma, nasal type oAnaplastic large cell lymphoma, ALK-positive type oCutaneous T cell lymphoma (mycosis fungoides, Sézary syndrome) oPrimary cutaneous CD30+ T-cell lymphoproliferative disorder oPrimary cutaneous anaplastic T-cell lymphoma oEnteropathy-associated T-cell lymphoma oHepatosplenic T-cell lymphoma oSubcutaneous panniculitis-like T-cell lymphoma oPrimary cutaneous gamma-delta T-cell lymphoma oPrimary cutaneous CD8+ aggressive epidermotropic lymphoma oPrimary cutaneous CD4+ small/medium T-cell lymphoma, Active malignancy other than the one treated in this research. Prior history of malignancies unless the patient has been free of the disease for = 2 years. However, patients with the following history are allowed: a. Basal or squamous cell carcinoma of the skin b. Carcinoma in situ of the cervix c. Carcinoma in situ of the breast d. Incidental histologic finding of prostate cancer (T1a or T1b) using the tumor, nodes, metastasis clinical staging system, Vaccinated with live, attenuated vaccines within 6 months of enrollment, Use of any standard or experimental anti-cancer drug therapy before the start of treatment except COP (cycloposphamide, vincristine, prednisone) in case of emergency (or high risk of tumor lysis syndrome) or etoposide for a maximum of 3 doses (at a maximum dose of 150mg/m2) for HLH (Hemophagocytic Lymphohistiocytosis)., A corticosteroids therapy > 1mg/kg lasting more than 14 days prior to Cycle 1 Day 1, Positive serology for Human Immunodeficiency Virus (HIV) and Human T-Lymphotrophic Virus (HTLV1), Active Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) infections defined as: HBV : HBs Ag positive / HBs Ag negative, anti-HBs antibody positive and anti-HBc antibody positive with detectable viral DNA - HCV : Anti-VHC antibody positive with detectable viral RNA

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified